CAS 1140909-48-3

cabozantinib (S)-malate

Description:

Cabozantinib (S)-malate is a small molecule inhibitor primarily used in cancer therapy, particularly for treating advanced renal cell carcinoma and hepatocellular carcinoma. It functions as a tyrosine kinase inhibitor, targeting multiple pathways involved in tumor growth and metastasis, including MET, VEGFR, and AXL. The (S)-malate form indicates that the compound is a salt derived from the malic acid, which enhances its solubility and bioavailability. Cabozantinib exhibits a complex structure that includes a central core with various functional groups, contributing to its pharmacological activity. The compound is typically administered orally and has a specific pharmacokinetic profile, including absorption, distribution, metabolism, and excretion characteristics that are crucial for its therapeutic efficacy. Side effects may include gastrointestinal disturbances, fatigue, and hypertension, reflecting its mechanism of action on vascular and cellular pathways. Overall, cabozantinib (S)-malate represents a significant advancement in targeted cancer therapies, offering a multifaceted approach to inhibit tumor progression.

Formula: C₃₂H₃₀FN₃O₁₀

InChI: InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1

InChI key: InChIKey=HFCFMRYTXDINDK-WNQIDUERSA-N

SMILES: C(NC1=CC=C(OC=2C3=C(C=C(OC)C(OC)=C3)N=CC2)C=C1)(=O)C4(C(NC5=CC=C(F)C=C5)=O)CC4.[C@H](CC(O)=O)(C(O)=O)O

Synonyms:

• (2S)-2-Hydroxybutanedioic acid compd.with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide(1:1)
• (2S)-2-hydroxybutanedioic acid
• Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4- quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
• Cabozantinib L-(-)-Apple Acid
• Cabozantinib L-Malate
• Cabozantinib Malate
• Cometriq
• N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide mono[(2S)-2-hydroxybutanedioate]
• N1-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
• Xl 184
• Cabozantinib S-malate
• Cabozantinib S-malate
• Cabozantinib L-Malate Salt
• N-[4-[(6,7-DiMethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxaMide (2S)-
• Cabozantinib (S)-Malate(XL-184)
• Cabozantinib Malate (XL184)
• XL184(S)-malate
• Cabozantinib malate, >=99%
• Cabozantinib (S)-malate (2S)-2-Hydroxybutanedioic acid compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)
• Smalate
• XL184(Cabozantinib malate)
• XL-184 (Malate)

Butanedioic acid, 2-hydroxy-, (2S)-, compd. with N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

CAS: 1140909-48-3

Formula: C₃₂H₃₀FN₃O₁₀

Purity: 98%

Color and Shape: Solid

Molecular weight: 635.5931

Ref: IN-DA000AJ8

Cabozantinib S-malate

CAS: 1140909-48-3

Cabozantinib S-malate

Purity: ≥98%

Molecular weight: 635.59g/mol

Ref: 54-BUP15407

Cabozantinib (S)-Malate

CAS: 1140909-48-3

Formula: C₂₈H₂₄FN₃O₅·C₄H₆O₅

Color and Shape: White To Off-White Solid

Molecular weight: 501.51 134.09

Ref: 4Z-C-284013

Cabozantinib (S)-Malate

CAS: 1140909-48-3

Color and Shape: Neat

Ref: 86-MM3947.00

Cabozantinib S-malate

CAS: 1140909-48-3

Cabozantinib S-malate (XL184) is the salt form of cabozantinib, an orally bioavailable, small molecule RTK inhibitor with potential antineoplastic activity.

Formula: C₃₂H₃₀FN₃O₁₀

Purity: 98% - >99.99%

Color and Shape: Solid

Molecular weight: 635.59

Ref: TM-T1797

Cabozantinib malate

CAS: 1140909-48-3

Formula: C₃₂H₃₀FN₃O₁₀

Purity: ≥ 98.0%

Color and Shape: White to off-white powder

Molecular weight: 635.59

Ref: 7W-GP4726

Cabozantinib (Phenylene-d4) L-Malate Salt

Controlled Product

CAS: 1140909-48-3

Applications Cabozantinib-d4 L-Malate Salt, is the labeled analogue of Cabozantinib L-Malate Salt (C051500), which is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis.
References Camp, R., et al.: Cancer, 86, 2259 (1999), Morello, S., et al.: J. Cell Physiol., 189, 285 (2001), Zhang, Y., et al.: Oncogene, 21, 217 (2002), Wells, S., et al.: J. Clin. Oncol., 28, 767 (2010),

Formula: C₂₈D₄H₂₀FN₃O₅·C₄H₆O₅

Color and Shape: Neat

Molecular weight: 639.62

Ref: TR-C051502

Cabozantinib L-Malate Salt

Controlled Product

CAS: 1140909-48-3

Applications Cabozantinib is a small molecule C-Met modulator. Cabozantinib acts as a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively. Cabozantinib shows dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature and extensive tumor cell apoptosis.
References Camp, R., et al.: Cancer, 86, 2259 (1999), Morello, S., et al.: J. Cell Physiol., 189, 285 (2001), Zhang, Y., et al.: Oncogene, 21, 217 (2002), Wells, S., et al.: J. Clin. Oncol., 28, 767 (2010),

Formula: C₂₈H₂₄FN₃O₅·C₄H₆O₅

Color and Shape: Neat

Molecular weight: 635.59

Ref: TR-C051500

Cabozantinib malate

CAS: 1140909-48-3

Inhibits MET, VEGFR1, VEGFR2; VEGFR3 receptor tyrosine kinases; antineoplastic

Formula: C₂₈H₂₄FN₃O₅·C₄H₆O₅

Purity: Min. 95%

Color and Shape: Off-White Powder

Molecular weight: 635.6 g/mol

Ref: 3D-FC64967